36
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Dupilumab efficacy and safety in adults with uncontrolled persistent asthma despite use of medium-to-high-dose inhaled corticosteroids plus a long-acting β2 agonist: a randomised double-blind placebo-controlled pivotal phase 2b dose-ranging trial.

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Dupilumab, a fully human anti-interleukin-4 receptor α monoclonal antibody, inhibits interleukin-4 and interleukin-13 signalling, key drivers of type-2-mediated inflammation. Adults with uncontrolled persistent asthma who are receiving medium-to-high-dose inhaled corticosteroids plus a long-acting β2 agonist require additional treatment options as add-on therapy. We aimed to assess the efficacy and safety of dupilumab as add-on therapy in patients with uncontrolled persistent asthma on medium-to-high-dose inhaled corticosteroids plus a long-acting β2 agonist, irrespective of baseline eosinophil count.

          Related collections

          Author and article information

          Journal
          Lancet
          Lancet (London, England)
          1474-547X
          0140-6736
          Jul 2 2016
          : 388
          : 10039
          Affiliations
          [1 ] Division of Pulmonary Allergy and Critical Care Medicine, University of Pittsburgh, Pittsburgh, PA, USA. Electronic address: wenzelse@upmc.edu.
          [2 ] Washington University School of Medicine, Saint Louis, MO, USA.
          [3 ] David Geffen School of Medicine at UCLA, Los Angeles, CA, USA.
          [4 ] Allergy and Respiratory Research Unit, Fundación CIDEA, Buenos Aires, Argentina.
          [5 ] Sanofi, Bridgewater, NJ, USA.
          [6 ] Regeneron Pharmaceuticals, Tarrytown, NY, USA.
          [7 ] Sanofi, Chilly-Mazarin, France.
          Article
          S0140-6736(16)30307-5
          10.1016/S0140-6736(16)30307-5
          27130691
          f325491c-b9b4-48cd-97ec-74b59105683d
          Copyright © 2016 Elsevier Ltd. All rights reserved.
          History

          Comments

          Comment on this article